A company emerging from the UPMC/University of Pittsburgh ecosystem, Generian entered an October 2026 research collaboration and exclusive option arrangement with Processa for an oral macrocyclic peptide FcRn antagonist.
The2019 FormD reports $12,989,999 sold within a $19,999,998 offering. The offering target is not cash already raised and does not establish2026 financing status.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Disease tags match recorded text mentions and require program-level verification.
Technology, programs & evidence
A company emerging from the UPMC/University of Pittsburgh ecosystem, Generian entered an October 2026 research collaboration and exclusive option arrangement with Processa for an oral macrocyclic peptide FcRn antagonist.
Program / service
Target / indication
Representative stage
Evidence & scope
Oral macrocyclic peptide FcRn antagonist program
FcRn · IgG-mediated autoimmune diseases
Research stage
No human results disclosed
Related news & literature
Company-name matches are discovery leads; verify entity identity and transaction roles in the original source.
Processa announced a research collaboration and exclusive option agreement with Generian Pharmaceuticals to advance an oral macrocyclic peptide FcRn antagonist program. The companies aim to develop oral alternatives to injectable treatments for IgG-mediated autoimmune diseases. The announcement disclosed neither human data for the peptide program nor financial terms; a separate BTK program received Phase 2 IND clearance.
Johnson & Johnson reported that 58% of patients receiving icotrokinra 200 mg achieved ACR20 at Week 16 in ICONIC-PsA 1, versus 41% with placebo. The oral IL-23 receptor peptide also showed skin responses. The company reported no new safety signals through Week 24; active psoriatic arthritis remains an investigational indication.
Entera reported $265.9 million in cash and cash equivalents at September 30, plus $6.5 million in restricted cash. Its November 6 update targets first site activation for an approximately 900-patient EB613 osteoporosis Phase 3 trial in late 2026. EB613 is an oral PTH(1-34) program, included here as an adjacent oral-peptide delivery development, not a cyclic-peptide candidate.
Johnson & Johnson reported that ICONIC-ASCEND met its Week 16 co-primary endpoints: PASI 90 responses were 55.2% with icotrokinra versus 3.6% with placebo, and IGA 0/1 responses were 70.4% versus 9.5%. At Week 28, the oral peptide met noninferiority criteria versus ustekinumab across multiplicity-controlled key secondary skin-clearance endpoints.
